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Abstract
Background: Hypocretin peptides participate in the regulation of sleep-wake cycle while deficiency in hypocretin signaling
and loss of hypocretin neurons are causative for narcolepsy-cataplexy. However, the mechanism responsible for alteration
of the hypocretin system in narcolepsy-cataplexy and its relevance to other central hypersomnias remain unknown. Here we
studied whether central hypersomnias can be associated with autoantibodies reacting with hypocretin-1 peptide present as
immune complexes.
Methodology: Serum levels of free and dissociated (total) autoantibodies reacting with hypocretin-1 peptide were
measured by enzyme-linked immunosorbent assay and analyzed with regard to clinical parameters in 82 subjects with
narcolepsy-cataplexy, narcolepsy without cataplexy or idiopathic hypersomnia and were compared to 25 healthy controls.
Principal Findings: Serum levels of total but not free IgG autoantibodies against hypocretin-1 were increased in narcolepsy-
cataplexy. Increased levels of complexed IgG autoantibodies against hypocretin-1 were found in all patients groups with a
further increase in narcolepsy-cataplexy. Levels of total IgM hypocretin-1 autoantibodies were also elevated in all groups of
patients. Increased levels of anti-idiotypic IgM autoantibodies reacting with hypocretin-1 IgG autoantibodies affinity purified
from sera of subjects with narcolepsy-cataplexy were found in all three groups of patients. Disease duration correlated
negatively with serum levels of hypocretin-1 IgG and IgM autoantibodies and with anti-idiotypic IgM autoantibodies.
Conclusion: Central hypersomnias and particularly narcolepsy-cataplexy are characterized by higher serum levels of
autoantibodies directed against hypocretin-1 which are present as immune complexes most likely with anti-idiotypic
autoantibodies suggesting their relevance to the mechanism of sleep-wake cycle regulation.
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Introduction
Hypocretin-1 (orexin A) and hypocretin-2 (orexin B) are two
neuropeptides produced by the same precursor molecule and
synthesized in neurons of the lateral hypothalamus [1,2].
Deficiency in hypocretin peptides production or defects in their
receptors were found to cause narcolepsy-like symptoms in
animals [3,4]. In humans, narcolepsy with cataplexy (NC) is
characterised by selective loss of hypocretin neurons in the brain
with low levels of hypocretin in the cerebro-spinal fluid (CSF)
[5,6,7]. Further evidence has accumulated supporting the causal
role of hypocretin deficiency in the origin of NC [8], however,
participation of hypocretin signaling in other forms of central
hypersomnia including narcolepsy without cataplexy (NWC) or
idiopathic hypersomnia (HI) is less understood, although a partial
hypocretin deficiency is possible in the former condition [9,10].
Selective loss or reduction of hypocretin neurons in NC together
with the tight association with HLA DQB1*0602, the recent
finding of polymorphisms in the T-cell receptor alpha locus and
the presence of elevated Tribbles homolog 2 antibody levels
suggest a possible autoimmune mechanism which so far remains
elusive [11,12,13]. Several studies failed to provide evidence for a
humoral autoimmune response against the hypocretin peptides
[12,14,15]. However, transfer of total IgG autoantibodies (auto-
Abs) from patients with NC to mice supported the presence of
functional autoAbs which might be relevant to NC [16,17] and
positive effect of intravenous IgG to normalize CSF hypocretin-1
level has been reported in an NC patient [18].
Failure to detect autoAbs response to the hypocretin peptides in
NC might be related to the prevailing concept of autoAbs being
the pure markers of autoimmune disease. However, another so far
largely unexplored concept is to consider the presence of natural
autoAbs reacting with self molecules including neuropeptides as a
physiological phenomenon [19,20]. Because any autoAbs exist as a
free fraction and as immune complexes, it is possible that relative
amount of free and complexed autoAbs against hypocretin
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availability and therefore can be associated with sleep/wake
dysregulation.
To address this question, in the present study, serum levels of
free and dissociated (total) autoAbs reacting with hypocretin-1
peptide were measured in patients with central hypersomnias
(including narcolepsy-cataplexy, narcolepsy without cataplexy and
idiopathic hypersomnia) and compared to healthy subjects and to
biological and clinical parameters relevant to sleep disorders.
Materials and Methods
Subjects
All subjects gave their written informed consent to participate in
the study, which was approved by the Montpellier University
Hospital’s ethics committee. Eighty-two patients (41 men and 41
women, mean age 38.5617.6) with chronic hypersomnias of
central origin including thirty-nine subjects with narcolepsy with
clear-cut cataplexy (NC), 17 with narcolepsy without cataplexy
(NWC), and 26 with idiopathic hypersomnia (HI) with long sleep
time participated in the study.
Diagnosis was made according to the revised International
Classification of Sleep Disorders (ICSD-2). All patients were
recorded for at least one night followed by the Multiple Sleep
Latency Test (MSLT) the next day consisting of five naps scheduled
at 2-h intervals starting at 9:00 h [21]. None of the patients were
taking psychostimulants for at least two weeks or anticataplectic
medications or any other medication known to influence sleep or
motor activity for at least one month prior to the sleep laboratory
recording. Patients were systematically evaluated for clinical
parameters including: disease duration, Epworth Sleepiness Scale
(ESS), cataplexy frequency scale (from 0 to 5) [22], hypnagogic
hallucinations, sleep paralysis, and body mass index (BMI).
Narcolepsy with cataplexy was diagnosed based on the presence
of excessive daytime sleepiness (EDS) and cataplexy, HLA
DQB1*0602 positivity and of at least two sleep onset REM
periods (SOREMPs) during the MSLT. The frequency of
cataplectic attacks was evaluated on a scale from 1 to 5 as
previously published [22]. Narcolepsy without cataplexy was
diagnosed based on the presence of EDS, mean sleep latency
below 8 min and at least two SOREMPs during the MSLT.
Idiopathic hypersomnia with long sleep time was characterized by
a complaint of constant EDS (ESS .12) and non refreshing naps
irrespective of their duration (.1 hour duration), an uninterrupted
and prolonged night-time sleep (.10 hours), sleep inertia and
sleep efficiency on the polysomnography above 90%. It should be
noted that 15 patients out of 26 affected with HI presented mean
sleep latency below 8 minutes on the MSLT. A diagnosis of
psychiatric disease according to DSM-IV [23] criteria was ruled
out as it was for obstructive sleep apnea syndrome on the basis of
the polysomnographic recording. All patients with an index of
respiratory events (apneas + hypopneas) greater than 10 or with
periodic leg movements index during sleep greater than 10 (except
for narcolepsy with cataplexy) were excluded from the study.
Twenty-five non overweight subjects (10 men and 15 women,
mean age 45.2616.7) were recruited as normal controls. All controls
were community-dwelling adults recruited from local associative
networks. Exclusion criteria were a positive history of neurological or
psychiatric disease, and/or the presence of sleep complaint including
EDS (none of them had an ESS score above 10).
Blood and CSF sampling
Both patients and controls underwent fasting venous blood
sampling between 7 to 8 AM with similar procedures at the
Montpellier Sleep Disorder Center. Sera were separated and
frozen immediately for further analysis and were handled similarly
between patients and controls before assay. A lumbar puncture
was performed in 35 patients (19 NC, 7 NWC, 9 HI) in order to
measure the CSF hypocretin-1/orexin A levels. CSF samples were
collected between 5 to 7 PM and stored immediately at 280uC
until use. Hypocretin-1 peptide levels were determined in
duplicate from CSF samples without prior extraction using
125I
radioimmunoassay kits from Phoenix Pharmaceuticals, Inc.
(Belmont, CA), according to the manufacturer’s instructions.
The detection limit was 10 pg/ml and intra-assay variability was
less than 10%. CSF hypocretin-1 levels of less than 110 pg/ml
were classified as low, between 110 and 200 pg/ml as intermediate
and above 200 pg/ml as normal [24].
Hypocretin peptide autoantibody assay
Serum levels of IgG, IgM and IgA autoAbs reacting with
hypocretin-1 peptide in all patients and controls were measured
using enzyme-linked immunosorbent assay (ELISA) technique.
The measurements were performed blinded for the diagnostic
phenotype. The hypocretin-1 peptide (Bachem AG, Bubendorf,
Switzerland) was coated on Maxisorp plates (Nunc, Rochester,
NY) using 100 ml and a concentration of 2 mg/ml in 100 mM
NaHCO3 buffer, pH 9.6 for 72 h at 4uC. Plates were washed (3
times) in phosphate-buffered saline (PBS) with 0.05% Tween 20,
pH 7.4, and then incubated overnight at 4uC with 100 mlo f
human sera diluted 1:200 in PBS to determine free autoAbs levels
or diluted 1:200 in dissociative 3M NaCl, 1.5 M glycine buffer,
pH 8.9 to determine total autoAbs levels. The optimal dilutions of
sera (1:200) were determined by several dilutions (1:100, 1:200,
1:400) to obtain for the same dilution mean OD levels of both free
and total autoAbs in the linear range of ELISA. The plates were
washed (36) and for the detection of IgG, IgM or IgA classes of
autoAbs incubated with 100 ml (1:2000) of rabbit anti human IgG,
anti human IgM or anti-human IgA antibodies, respectively, all
conjugated with alkaline phosphatase (Sigma, St. Louis, MO) for
3 h at room temperature. Then, following washing (36), 100 mlo f
p-nitrophenyl phosphate solution (Sigma) was added as alkaline
phosphatase substrate. After 40 min of incubation at room
temperature, the reaction was stopped by adding 3N NaOH.
The optical density (OD) was determined at 405 nm using a
microplate reader. Blank OD values resulting from the reading of
plates without addition of human sera were subtracted from the
sample OD values. Each determination was done in duplicate.
The variation between duplicate values was less than 5%. Presence
of hypocretin-1 autoAbs in immune complexes was estimated by
ratios between levels of total (dissociated) and free autoAbs and
their percentage relative to the total levels of autoAbs was
calculated.
Hypocretin autoantibody purification
Total IgG was purified from 0.5 ml of serum samples from
eleven randomly selected NC patients using Immobilized Protein
G Plus (Pierce, Rockford, IL) according to manufacturer
instructions. Presence of IgG in the eluates was confirmed by
western blot with peroxidase-conjugated goat anti-human IgG
antibodies (Dako, Copenhagen, Denmark).
Individual samples of total IgG purified from patients’ sera were
combined into one pool which was further purified using affinity
chromatography with hypocretin-1 peptide (Bachem) coupled to
the pre-activated beads according to manufacturer’s instructions
(UltraLink, Pierce). Purified IgG were concentrated by lyophiliza-
tion and dilution to 50 mg/ml in water. Presence of IgG autoAbs
Hypocretin Autoantibodies
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below) on a rat hypothalamic homogenate.
Western blot
To validate by western blot the presence of hypocretin reactive
IgG autoAbs in affinity purified samples from NC patients, two
Wistar rats were killed by decapitation and entire blocks of the
hypothalamus were dissected and placed into ice-cold lysis buffer
containing 0.1% protease inhibitor cocktail (Sigma). Tissues were
manually homogenized. Vials were placed on ice for 15 min and
then centrifuged for 15 min at 4uC and 12,000 rpm. The
supernatant containing proteins was collected and stored at
280uC until analysis. Protein samples in duplicates (25 mg,
50 mg and 75 mg) were separated on 20% acrylamide SDS gel in
Tris-Glycine buffer and transferred to a nitrocellulose membrane
(GE Healthcare, Orsay, France), which was blocked for 1 h at
room temperature with 5% (w/v) non-fat dry milk in TBS
(10 mmol/L Tris, pH 8; 150 mmol/L NaCl) plus 0.05% (w/v)
Tween 20. Then, the membrane was cut into two parts and each
part was incubated overnight at 4uC with human hypocretin-1
affinity purified IgG autoAbs (1:10) or with rabbit anti-hypocretin-
1 IgG antibody (1:1000, Bachem). After three washes in a blocking
solution of 5% (w/v) non-fat dry milk in TBS/0.05% Tween 20,
membranes were incubated for 1 h with goat anti-human IgG
(1:5000, Dako) or anti-rabbit IgG (1:5000, SantaCruz Biotechnol-
ogy) secondary antibodies, respectively, both peroxidase-conjugated.
After three washes, the peroxidase reaction was revealed using the
ECL detection kit (GE Healthcare). Protein bands were compared
with the molecular weight standard (Precision Plus, BioRad)
and films were scanned using ImageScanner III (GE Healthcare).
For negative controls, after protein transfer in a separate set of
membranes, only secondary antibodies were applied and
revealed.
Anti-idiotypic autoantibody assay
Serum levels of anti-idiotypic IgM autoAbs reacting with anti-
hypocretin-1 IgG autoAbs affinity-purified from NC patients’ sera
were measured in all patients and controls using ELISA technique
as described above with some modifications. Briefly, patients’ anti-
hypocretin-1 IgG autoAbs were coated on Maxisorp plates (Nunc)
at 2 mg/ml in 100 mM NaHCO3 buffer; sera (diluted 1:100 in
PBS) from patients and controls were applied overnight and
presence of bound IgM autoAbs was detected using rabbit anti-
human IgM antibodies conjugated to alkaline phosphatase
(1:2000, Sigma) which was developed as described above.
Statistical analysis
Data were analyzed and graphs were plotted using the
GraphPad Prism 5.02 program (GraphPad Software Inc., San
Diego, CA). Levels of autoAbs were compared using ANOVA or
Kruskal-Wallis tests according to normality tests and post hoc
Tukey-Kramer or Dunn’s tests were correspondingly performed.
NC group was additionally compared to other groups using the
Student’s t-test or the Mann-Whitney (MW) test according to
normality test. Correlations between autoAbs levels and clinical
parameters were calculated using the Spearman two-tail test.
Bonferroni correction for multiple tests was applied by multiplying
p-values by 9 (number of clinical parameters tested). Clinical
parameters were compared between the patient’s groups using
ANOVA, Kruskal-Wallis or Chi-square tests. In all cases, p,0.05
was considered to be statistically significant.
Results
Clinical and biological characteristics
Clinical and biological characteristics of patients with central
hypersomnia are presented in Table 1. Patients’ groups were not
significantlydifferentwithregardtoage,BMI,andESSscale.There
were gender differences between hypersomnia populations, with
more males in the NC group compared to both HI and NWC
groups. As expected, the presence of hypnagogic hallucinations,
sleep paralysis, number of SOREMPs, mean sleep latency and CSF
hypocretin-1 levels differ between the patient groups. Low CSF
hypocretin-1levels,i.e. below110 pg/ml was found in38 among39
Table 1. Clinical and biological characteristics of patients with central hypersomnia including narcolepsy-cataplexy (NC),
narcolepsy without cataplexy (NWC) and idiopathic hypersomnia (HI).
Patients characteristics NC N=39 NWC N=17 HI N=26 p-values
Males/Females 28/11 5/12 8/18 p,0.001
a,b
Age, years 40.4618.9 37.9618.9 36.4614.8 p=0.65
Disease duration, years 21.2618.8 19.1617.6 15.4613.6 p=0.47
BMI, (kg/m
2) 25.864.3 23.963.6 24.164.3 p=0.14
ESS score 18.663.5 16.264.1 17.363.8 p=0.08
Cataplexy score 3.061.5 0 0
Hallucinations, % 65.8 35.3 25.9 p=0.004
a,b
Sleep paralysis, % 47.4 23.5 11.1 p=0.007
a,b,c
MSLT
SOREMP, n 3.561.2 3.261.7 0.360.5 p,0.0001
b,c
Mean sleep latency, min 5.262.9 5.662.8 7.763.9 p=0.01
b,c
CSF hypocretin-1, Mean levels (pg/ml) Low levels
(,110 pg/ml), %
N=19 33.4671.8 94.7 N=7 3496114.80 N=9 4586140 0 p,0.0001
b
Significant differences,
aNC vs. NWC,
bNC vs. HI,
cNWC vs. HI.
doi:10.1371/journal.pone.0013320.t001
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132 pg/ml) and none in NWC (one patient was within the
intermediate range, i.e. 148 pg/ml) or in HI patients.
Hypocretin-1 autoAbs assay
Serum levels of free IgG autoAbs directed against hypocretin-1
were lower in all three groups of patients with central
hypersomnias than in controls (Kruskal-Wallis test p,0.0001,
Fig. 1A). In contrast, levels of hypocretin-1 total IgG autoAbs were
not lower, and even higher in the NC group as compared to
controls and NWC (Fig. 1B). These changes in the levels of total
and free IgG autoAbs resulted in a higher percentage of these
autoAbs present in immune complexes in all patients groups
(median 6SD, NC, 8268%, NWC, 77615%, HI, 7768% and
controls 6269%, Kruskal-Wallis test p,0.0001, Fig. 1C). More-
over, the levels of immune complexes of hypocretin-1 autoAbs
were significantly higher in the NC group comparative to other
central hypersomnias (Fig. 1C).
Serum levels of free IgM class of autoAbs directed against
hypocretin-1 were found elevated in the HI group vs. controls
(Fig. 2A). Levels of total IgM autoAbs directed against both
peptides were increased in all patients with central hypersomnia
and this increase was more pronounced in the HI group (Fig. 2B).
Increased percentage of hypocretin-1 IgM autoAbs present in
immune complexes was found in the NWC and HI groups
comparative to controls (Fig. 2C).
Serum levels of free IgA class of autoAbs directed against
hypocretin-1 were lower in the NC and HI groups vs. controls
(Fig. 3A). No significant differences in levels of total IgA autoAbs
were detected (Fig. 3B). More immune complexes of hypocretin-1
IgA autoAbs were found in the NC and HI groups vs. controls
(Fig. 3C).
Correlations of hypocretin-1 autoAbs with clinical
parameters
Disease duration. After correction for multiple tests, we
found significant negative correlations between disease duration
and levels of hypocretin-1 free IgG autoAbs (r=20.35, p=0.013),
and levels of hypocretin-1 free IgM autoAbs (r=20.39, p=0.003).
In contrast, disease duration correlated positively with the IgA
class of total and free hypocretin-1 autoAbs (r=0.4, p=0.002, and
r=0.31, p=0.04, respectively).
Body mass index (BMI). After correction for multiple tests,
no significant correlations were found between BMI and
hypocretin-1 autoAbs levels. However, before correction, BMI
correlated negatively with levels of hypocretin-1 free IgG in
patients with central hypersomnia combined (r=20.28, p=0.01)
and in the NC group (r=20.36, p=0.02).
Cataplexy. No significant correlations were found in NC
subjects between the frequency of cataplexy and hypocretin-1
autoAbs. The presence of IgG immune complexes with hypocretin-
1 correlated positively with the frequency of cataplexy (r=0.24,
p=0.03) before Bonferroni correction.
Daytime sleepiness. No significant correlations were found
between the ESS score or mean sleep latency and hypocretin
autoAbs after correction for multiple tests. Significant correlations
for ESS with levels of hypocretin-1 free IgG autoAbs in the NC
group (r=0.39, p=0.016), or mean sleep latency with levels of
immune complexes of hypocretin-1 IgA autoAbs (r=0.35,
p=0.035) were found before corrections in patients with NC.
Hallucinations, sleep paralysis and sleep-onset REM
periods (SOREMP). No significant correlations between
hypnagogic hallucinations, sleep paralysis and SOREMP with
hypocretin-1 autoAbs were found in the NC and NWC groups or
all groups of patients combined.
CSF hypocretin-1 levels. No significant correlations were
found between CSF hypocretin-1 levels and hypocretin-1 autoAbs
after correction for multiple tests. However, before correction,
CSF hypocretin-1 levels correlated negatively with free IgG
autoAbs against hypocretin-1 in the NC group (r=20.36,
p=0.04).
Western blot. Using hypocretin-1 reactive IgG autoAbs
affinity purified from sera samples of NC patients we were able
Figure 1. Serum levels of free (A), total (B) and percentage of
immune complexes (C) of IgG autoAbs reactive with hypocre-
tin-1 in subjects with central hypersomnia and controls. Bars
show medians, *p,0.05, **p,0.01 Dunn’s tests vs. controls. #a,
p,0.05, two-tails, #b, p,0.05, one-tail, Mann-Whitney -tests.
doi:10.1371/journal.pone.0013320.g001
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rat hypothalamic homogenate (Fig. 4A). The band of the same size
was detected using a commercial rabbit anti-hypocretin-1
antiserum (Fig. 4B) which was previously shown to correspond
to the hypocretin precursor protein [25]. The intensity of the band
corresponded to the amount of protein homogenates. In a negative
control experiment, when no NC patient’s affinity purified
hypocretin-1 IgG autoAbs or rabbit anti-hypocretin-1 IgG
antibody were added, no bands corresponding to molecular
weight of 16 KDa were detected.
Anti-idiotypic IgM autoantibodies. Serum levels of anti-
idiotypic IgM autoAbs reacting with hypocretin-1 IgG autoAbs
affinity purified from sera of NC patients differed significantly
among four groups (ANOVA, p=0.014). All patient groups
showed elevated levels of these anti-idiotypic IgM autoAbs as
compared to controls (Fig. 5).
Figure 2. Serum levels of free (A), total (B) and percentage of
immune complexes (C) of IgM autoAbs reactive with hypocretin-
1 in subjects with central hypersomnia and controls. Bars show
medians,*p,0.05,**p,0.01Dunn’stestsvs.controls.# p,0.05two-tails,
Mann-Whitney -test vs. controls.
doi:10.1371/journal.pone.0013320.g002
Figure 3. Serum levels of free (A), total (B) and percentage of
immune complexes (C) of IgA autoAbs reactive with hypocretin-
1 in subjects with central hypersomnia and controls. Bars
show medians, **p,0.01 Dunn’s tests vs. controls. # p,0.05, two-tails,
Mann-Whitney-tests vs. controls and #a, p,0.05, one-tail Mann-Whitney
test.
doi:10.1371/journal.pone.0013320.g003
Hypocretin Autoantibodies
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clinical parameters
After correction for multiple tests, we found significant negative
correlations between disease duration and levels of anti-idiotypic
IgM autoAbs reacting with hypocretin-1 IgG autoAbs (r=20.39,
p=0.004) in all patients’ groups combined. Before Bonferroni
correction, levels of anti-idiotypic IgM autoAbs correlated
negatively with CSF hypocretin-1 levels in all patients’ groups
(r=20.32, p=0.03, one-tail), in the NC group (r=20.4, p=0.04,
one-tail) and in the HI group (r=20.7, p=0.02, two-tails).
Discussion
The present data revealed altered characteristics of hypocretin-1
reactive autoAbs in subjects with central hypersomnia. We found
that levels of hypocretin-1 free IgG autoAbs were lower in NC,
NWC and HI groups of patients than in controls. These data are
in agreement with a previous report showing low levels of free
hypocretin autoAbs in NC patients [15]. Because a fraction of
autoAbs exist in immune complexes which are not detectable in
normal assays, we measured the levels of total autoAbs reactive
with hypocretin-1 peptide using a NaCl-glycine buffer which
dissociates immune complexes. With this approach, we found that
in contrast to the free fraction of hypocretin-1 autoAbs, total IgG
autoAbs are increased in the patients with NC. We acknowledge
some limitation of this analysis since few values of total IgG
autoAbs had OD above 2.5 which might not be very accurate and
could underestimate the actual autoAbs levels. Furthermore, by
analyzing the ratios between total and free autoAbs levels which
shows proportion of complexed autoAbs, we found that all three
groups of patients including NC, NWC and HI had higher
percentage of hypocretin-1 autoAbs present in immune complexes
than controls. In addition, using hypocretin-1 reactive IgG
autoAbs affinity purified from sera samples of NC patients we
detected a band that correspond to the hypocretin precursor
protein in rat hypothalamic homogenate in Western Blotting.
Increased levels of immune complexes of hypocretin-1 IgG
autoAbs especially reported in NC may signify deficient
hypocretin signalling as has been shown recently for a-melano-
cyte-stimulating hormone (a-MSH) autoAbs [26]. However, the
relevance of systemic hypocretin to the central hypocretin
signaling is currently unknown. Peripheral sources of hypocretin,
even subject to controversy, may exist [8,27,28]. Whether
hypocretin-reactive autoAbs are functionally significant remain
to be determined as most of immunoglobulins do not cross the
blood-brain barrier under physiological condition. Recent study
reported altered levels of main subclasses of total IgG in NC and
HI patients which further support the involvement of the humoral
immune response in central hypersomnia [29].
The composition of immune complexes of hypocretin-1 autoAbs
is most likely with anti-idiotypic autoAbs since increased levels of
such autoAbs was found in all three groups of patients with central
hypersomnia. Although we checked for the IgM class of anti-
idiotypic autoAbs, it is probable that other immunoglobulin classes
including IgG may form such complexes. The presence of anti-
idiotypic autoAbs per se is a natural phenomenon constituting the
anti-idiotypic network which role is believed to prevent autoimmu-
nity via neutralization of persistent antibodies to endogenous or
exogenousantigens [30]. Thus,our finding of elevated levels of anti-
idiotypic autoAbs in patients with central hypersomnia may be
biologically significant in controlling the peripheral hypocretin
availability. Nevertheless, considering the eventual complementar-
itiesbetweenthe paratopeofanti-idiotypicautoAbsand the antigen,
whichisinthiscase hypocretin-1peptideoracross-reactingprotein,
one cannot exclude binding of these autoAbs to the hypocretin
receptors.Suchaphenomenonwasshown,forinstance,fortheanti-
idiotypic autoAbs against anti-beta endorphin autoAbs, being able
to antagonize beta-endorphin binding to opiate receptors in some
subjects with major depression [31]. Whether hypocretin-1 anti-
idiotypic autoAbs may interfere with hypocretin signalling relevant
to hypersomnia or if they are simply markers of disease progression
should be clarified in further studies.
Presence of elevated levels of IgM class of autoAbs normally
reflects recent antigenic stimulation [32]. Unexpectedly, we found
increased levels of hypocretin-1 total IgM autoAbs and anti-
idiotypic IgM autoAbs in all three groups of patients and
particularly significant in the HI group. These results may signify
a continuous antigenic stimulation during the disease progression,
finding supported by a negative correlation noted between disease
duration and levels of IgM autoAbs.
Presence of elevated levels of IgA class of autoAbs may reflect
luminal, most commonly intestinal or respiratory tracts origin of
antigens [33]. We found that NC and HI patients had increased
percentage of immune complexes of hypocretin-1 IgA class of
autoAbs. This finding may signify that class switch from IgM to
IgA hypocretin-1 autoAbs is triggered by a luminal antigen. We
previously showed existence of sequence homology between
hypocretin-1 peptide and some microorganisms including gut
microflora [34] which may account for the concept of molecular
mimicry responsible for production of cross-reactive autoAbs [35].
Figure 4. Western blot detection of a band corresponding to
the hypocretin precursor protein (16 KDa) in the rat hypotha-
lamic homogenate. A. Detection using human IgG autoAbs affinity
purified for hypocretin-1 peptide from sera of NC patients. B. Detection
using commercial rabbit anti-hypocretin-1 antiserum. Columns 1, 2 and
3 correspond to 75, 50 and 25 mg, respectively, of protein amount from
the hypothalamic homogenate loaded into the gel. Molecular weight
markers (KDa) are shown on the left.
doi:10.1371/journal.pone.0013320.g004
Figure 5. Serum levels of anti-idiotypic IgM autoAbs reactive
with hypocretin-1 IgG autoAbs in subjects with central
hypersomnia and controls. Bars show means, *p,0.05, Tukey’s test
vs. controls. # p,0.05 and ## p,0.01, Student’s t-test, two-tails vs.
controls.
doi:10.1371/journal.pone.0013320.g005
Hypocretin Autoantibodies
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anti-streptococcal and Tribbles homolog 2 antibodies [13,36].
Disease duration correlated positively with levels of IgA hypocretin
autoAbs, suggesting an increase of luminal antigenic stimulation to
produce such autoAbs during disease progression that again may
be triggered by yet unidentified molecular mimicry of microor-
ganisms.
Although several sleep-related characteristics such as daytime
sleepiness, sleep onset latency and hypnagogic hallucinations were
significantly associated with serum levels of hypocretin-1 autoAbs
in patients with central hypersomnia before correction for multiple
tests, these associations were not significant after such a correction
and, therefore, functional significance of these correlations should
be individually verified in further studies. Excessive daytime
sleepiness is a hallmark symptom of primary central hypersomnias;
however, the neural basis of sleepiness remains unclear in most
disorders. Based on the present data, the relevance of hypocretin-1
reactive autoAbs in mechanisms underlying sleepiness may be
hypothesized even if the relationship between free/immune-
complexed systemic immunoglobulins and the hypothalamic sleep
control remain to be clarified.
We may acknowledge several limitations of our study: first,
there was no measurement of CSF hypocretin-1 autoAbs. Second,
we did not assay serum levels of hypocretin to see their possible
correlations with hypocretin autoAbs. Third, patients with HI,
NWC and controls were not HLA matched to the patients with
NC. The sera was taken after long duration of diseases that has
decreased the chance to picking up major alterations of antibody
levels with relative overlap even with between-group significant
differences. Finally, the number of control subjects was relatively
small.
In conclusion, we found that subjects with NC display increased
serum levels of hypocretin-1 reactive total IgG autoAbs and all
three groups (NC, NWC and HI) show increased serum levels of
complex-forming hypocretin-1 autoAbs most likely with anti-
idiotypic autoantibodies. Future studies should precise whether
hypocretin-reactive autoAbs are involved in physiological regula-
tion of hypocretin availability relevant to arousal and sleep/
wakefulness
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